Targeting HIV Beyond Protease and Reverse Transcriptase Inhibitors by Kuritzkes, Daniel R. & Walker, Bruce D.
Cell
284
smaller pieces of DNA via recombination, or as modula- opportunistic infections and malignancies in male ho-
mosexuals heralded the onset of the AIDS epidemic. Thetors of gene expression through methylation of cis-act-
ing transcriptional regulatory elements. Like some other subsequent identification of human immunodeficiency
virus as the etiologic agent of AIDS led quickly to ainfamous mucosal pathogens (H. influenzae and Neisse-
ria spp), H. pylori uses slipped-strand mispairing to spur search for agents capable of inhibiting viral replication
and restoring immune function. Since the first reportits adaptive evolution within its host niche: the resulting
frame-shift mutations act as switches to turn production of successful pharmacologic impact on HIV-1 disease
progression in 1987, fifteen drugs belonging to threeof proteins on or off. There is extensive discussion of
how variation in gene content in the organism’s cag separate classes (nucleoside reverse transcriptase inhibi-
tors [NRTI’s], non-nucleoside RT inhibitors [NNRTI’s],pathogenicity island (and the PAI’s type IV secretion
system) are intimately linked to host responses. and protease inhibitors [PI’s]) have been approved for
treatment of HIV-1 infection by the US Food and DrugThe editors note in their preface that they wanted
to create a book that “would summarize and review Administration, and over a dozen more are currently in
development. The use of these agents has dramaticallythe accumulated knowledge on this important human
pathogen.” They have succeeded. In 2004, exactly changed the clinical course of HIV-1 infection for those
fortunate enough to have access (Palella et al., N. Engl.twenty years will have elapsed since the “big gulp.” The
chances of making major advances in our understanding J. Med. 338, 853–860, 1998). At the same time, this
rapidly evolving field and the need to keep abreast ofthe biology of this microorganism and the determinants
of its host relationships could not be brighter. DNA mi- new developments represents a growing challenge to
croarrays containing more than 98% of the known ORFs clinicians and researcher alike.
of the two sequenced strains are now available for whole Antiretroviral Therapy summarizes much of the prog-
genome genotyping of clinical isolates (Salama et al., ress that has been made in the development of antiret-
Proc. Natl. Acad. Sci. USA 97, 14668–14673, 2000). Un- roviral therapeutic agents. Edited by Erik De Clercq, who
dertaking a comprehensive screen for the presence or also coauthored several of the chapters, this book offers
absence of bacterial genes in strains taken from defined a broad overview of each of the different classes of
patient populations, or from individuals over the course drugs currently available for inhibition of HIV and reviews
of their infection, provides an opportunity to build a progress toward the development of novel classes of
knowledge base for correlating microbial and host phe- anti-HIV-1 therapeutics. The major focus of the book is
notypes with H. pylori genotypes. Genetically manipulat- on the inhibitors themselves, rather than on their clinical
able and environmentally defined animal models are be- use, so much so that a more accurate title might have
coming available to model host traits thought to function been Antiretroviral Agents. Those seeking a discussion
as risk factors for development of severe pathology. of the vexing questions of when to initiate therapy, when
Methods are emerging for monitoring bacterial gene to change from one regimen to another, how to manage
expression in vivo (Rokbi et al., Infect. Immunol. 69, treatment-related toxicities, or under what circum-
4759–4766, 2001), raising the hope that both host and stances treatment interruption might be warranted will
microbial gene expression can be monitored simultane- find little discussion of those treatment-related topics
ously during the course of infection. The feasibility of in this edition. Readers will, however, find a thorough
conducting screens for essential H. pylori genes has discussion of the agents themselves, written in highly
been demonstrated (Chalker et al., J. Bacteriol. 183, readable style and containing helpful figures and tables.
1259–1268, 2001). The first reported large-scale pro- Unfortunately, given the rapid pace of antiretroviral drug
karyotic protein-protein interaction map has been pro- development, much of the material is already seriously
duced using information from the sequenced H. pylori out of date. Despite a publication date of 2001, most of
genome and a version of the yeast two-hybrid system the references date from 1999 or before, which in the
(Rain et al., Nature 409, 211–215, 2001). Amidst all of end is the most serious shortcoming of the book.
this emerging technology, this book should serve as an The chapters on reverse transcriptase inhibitors and
invaluable guide for placing new results into the broad- protease inhibitors provide thorough summaries of
est possible context. these agents. Particularly helpful is the thorough discus-
sion of pathways for phosphorylation and metabolism
Andrew J. Syder and Jeffrey I. Gordon of the nucleoside and nucleotide analogs, which must
Department of Molecular Biology and Pharmacology be activated intracellularly to their triphosphate or di-
Washington University School of Medicine phosphate forms, respectively. Detailed discussions of
Saint Louis, Missouri 63110 the calculated approach to the development of new
agents such as ABT-378 through structure/function
analyses provide interesting insights into drug discovery
Targeting HIV: Beyond Protease from authors who were involved in these processes,
but results of promising clinical studies that formed theand Reverse Transcriptase Inhibitors
basis for FDA approval are not discussed. Structural
considerations are also prominent in the chapter on the
non-nucleoside RT inhibitors (NNRTIs), which is illus-Antiretroviral Therapy
trated by helpful figures showing the structural basis forEdited by E.D.A. De Clercq
interaction of these inhibitors with RT; the chapter onWashington, DC: ASM Press (2001). 359 pp. $99.95
the protease inhibitors would have been strengthened
by inclusion of similar figures. Chapters on the RT inhibi-
tors and protease inhibitors would have been enhancedTwo decades ago, a report by the Centers for Disease
Control and Prevention (CDC) of an unusual cluster of by a discussion of the toxicities of these agents, but
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this area was largely omitted. For example, there is no to therapeutic immunization that are now nearing or in
discussion of mitochondrial toxicity in the chapter of clinical trials, such as the use of DNA vaccines, ca-
nucleoside RT inhibitors, and only brief mention of lipo- narypox vectors, and antigen-pulsed dendritic cells.
dystrophy in the protease inhibitor chapter. The final chapters in the book focus on drug resis-
The chapters on alternative targets for HIV inhibition tance, drug-drug interactions, and combination therapy.
provide important reviews of new approaches, but are The chapter on emergence of drug-resistant HIV-1 in-
among the most seriously impacted by the apparent cludes a scholarly discussion of recently identified
slow road to publication of this edition. The chapter on mechanisms of zidovudine resistance, although it over-
cellular receptors as targets for anti-HIV agents focuses laps significantly with the chapter on drug resistance
primarily on inhibition of the chemokine receptor CXCR4 testing. Both chapters include a table of important drug
by the bicyclam AMD3100. The chemokine receptors resistance mutations, but a number of discordances can
CCR5 and CXCR4 serve as coreceptors for HIV, and be found. A cumbersome aspect of ASM style comes
considerable effort is being devoted to the development to the fore in these chapters as well. Abstracts are cited
of chemokine receptor blockers. Unfortunately, clinical in the text, rather than with published references at the
development of AMD3100 has been halted due to toxici- end of the chapter. Because so much of the work cited
ties observed in phase I clinical trials. The chapter could is available only in abstract form, on many pages whole
have been expanded to encompass inhibitors such as paragraphs are taken up by these citations. Moreover,
T-20 that interact with the transmembrane subunit of in 2001, one is left questioning why the main evidence
HIV-1 envelope (gp41) to prevent fusion of the viral and in support of some major statements made derives from
cell membranes (Kilby et al., Nat. Med. 4, 1302–1307, abstracts dated 1998 and earlier. The chapter on combi-
1998). The chapter on integrase inhibitors focuses al- nation therapy provides a detailed review of the major
most entirely on nonspecific inhibitors whose mecha- clinical trials on which the current approach to antiret-
nism of action depends on binding to DNA. Most of roviral therapy is based, but once again there are impor-
these compounds are not serious candidates for clinical tant treatment issues not discussed, particularly the tox-
development. The recent ground-breaking work of Ha- icities associated with this therapy. The brief chapter
zuda and colleagues on the identification of compounds on drug-drug interactions has an excellent table of the
that specifically inhibit the integrase-mediated strand most significant interactions associated with drugs used
transfer reaction is not discussed (Hazuda et al., Science in the treatment of HIV infection and its complications.
287, 646–650, 2000). However, the use of ritonavir to enhance the pharmaco-
Agents that target the transcriptional regulation of kinetic profile of other protease inhibitors, which has
HIV-1 are covered in two chapters, one that focuses on become a mainstay of current treatment strategies, is
inhibitors of Tat and Rev, and another that focuses on discussed in only three short paragraphs.
cellular proteins involved in HIV-1 gene expression. Al- In summary, this book provides solid background in-
though both chapters have excellent discussions of the formation for those seeking an introduction to HIV inhibi-
regulatory pathways that govern HIV-1 transcription and tors, but interested readers will have to search else-
translation, there is considerable overlap. Surprisingly, where to fill in the considerable gaps and to obtain
attempts to inhibit HIV expression through gene thera- information on the current state of the art. In an age in
pies that direct overexpression of Tat-binding se- which plenary sessions of international meetings are
quences (TAR decoy) or trans-dominant Rev mutants posted on the world-wide web and authoritative summa-
(RevM10) are not discussed (Bevec et al., Proc. Natl. ries of every AIDS conference are available almost in-
Acad. Sci. USA 89, 9870–9874, 1992; Sullenger et al., Cell stantly on the internet, traditional print media face a
63, 601–608, 1990). Equally surprising is the omission of daunting challenge in providing up-to-date, relevant in-
ribozymes from the chapter on oligonucleotides as formation in a timely manner.
HIV-1 inhibitors. In fact, gene therapy and stem cell
transplantation as possible approaches to the treatment
Daniel R. Kuritzkes1 and Bruce D. Walker2of HIV infection are not addressed at all.
1 University of Colorado Health Sciences CenterOne of the newest areas of interest related to antiret-
Denver, Colorado 80262roviral therapy is the use of these agents alone or in
2 Massachusetts General Hospitalcombination with other interventions to augment im-
and Harvard Medical Schoolmune responses to HIV. This topic is dealt with in part
Boston, Massachusettsin a chapter on therapeutic vaccines, which provides a
review of the field up through 1998. However, a wealth
of recent information providing strong rationale for ther-
Of Course Sex Mattersapeutic immunization is not cited, again apparently be-
cause of a long delay from the time the chapters were
written until the book was published. Discussions of the
Exploring the Biological Contributions to Humanimpact of early treatment on immune responses (Oxe-
nius et al., Proc. Natl. Acad. Sci. USA 97, 3382–3387, Health—Does Sex Matter?
2000; Rosenberg et al., Science 278, 1447–1450, 1997), Edited by Theresa Wizemann and Mary-Lou Pardue
the ability of a protease inhibitor, HAART, to promote Washington, DC: National Academy Press (2001).
production of new naive cells (Autran et al., Science 267 pp. $44.95
277, 112–116, 1997), and the effect of treatment interrup-
tion on immunologic boosting in acute and chronic in-
Several years ago, I gave a talk at an International Wom-fection are not included. Moreover, readers will have to
go to other sources to read about many approaches en’s Day luncheon on the then newly discovered SRY
